Non-factor replacement therapies in hemophilia

 

 

Scroll to top

• References

• 1 Ragni MV. Targeting antithrombin to treat hemophilia. N Engl J Med 2015; 373: 389-391.
• 2 Shima M, Hanabusa H, Taki M. et al. Factor VIIImimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med 2016; 374: 2044-2053.
• 3 Klamroth R. A new era of treatment for patients with haemophilia A?. Hämostaseologie 2017; 37: 216-218.
• 4 Scharf RE. Hot topic: Alloantibodies to therapeutic FVIII and the use of emicizumab in hemophilia A. Hämostaseologie 2016; 36: 195-198.
• 5 Tiede A. Thrombotic risks of non-factor replacement therapies in hemophilia. Hämostaseologie 2017; 37: 307-310.
• 6 Oldenburg J, Mahlangu JN, Kim B. et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377: 809-818.
• 7 Pasi KJ, Rangarajan S, Georgiev P. et al. Targeting of antithrombin in hemophilia A or B with RNAi therapy. N Engl J Med 2017; 377: 819-828.